XML 65 R52.htm IDEA: XBRL DOCUMENT v3.10.0.1
Collaborative Arrangements - Reimbursement of R and D Costs (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Research and Development Reimbursement                      
Total reduction to R and D expense                 $ 9,112 $ 23,540 $ 90,737
Revenue $ 15,737 $ 12,838 $ 23,476 $ 8,319 $ 4,515 $ 4,275 $ 3,509 $ 3,087 60,370 15,386 48,648
Profit sharing revenue                      
Research and Development Reimbursement                      
Revenue                 3,275    
Mylan                      
Research and Development Reimbursement                      
Total reduction to R and D expense                 7,515 23,427 83,490
Revenue                 24 102 15,102
Collaboration profit sahring revenue related to profit sharing payments receivable                 3,300    
Mylan | Development and Commercialization Agreement                      
Research and Development Reimbursement                      
Total reduction to R and D expense                 7,500    
Mylan | Registrational Activities | Development and Commercialization Agreement                      
Research and Development Reimbursement                      
Total reduction to R and D expense                 4,500    
Mylan | Profit Sharing Payments | Development and Commercialization Agreement                      
Research and Development Reimbursement                      
Total reduction to R and D expense                 3,000    
Mylan | Profit sharing revenue                      
Research and Development Reimbursement                      
Revenue                 3,300    
Janssen                      
Research and Development Reimbursement                      
Total reduction to R and D expense                 1,597    
Revenue                 31,053    
Alfasigma                      
Research and Development Reimbursement                      
Total reduction to R and D expense                     7,113
Revenue                 $ 10,678    
Other                      
Research and Development Reimbursement                      
Total reduction to R and D expense                   $ 113 134
Revenue                     $ 500